203 related articles for article (PubMed ID: 38021507)
1. Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care.
Kumar T; Dutta RR; Thakre S; Singh A; Velagala VR; Shinde RK
Cureus; 2023 Oct; 15(10):e47869. PubMed ID: 38021507
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
4. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.
Fleming L; Agnew S; Peddie N; Crawford M; Dixon D; MacPherson I
Breast; 2022 Aug; 64():63-84. PubMed ID: 35609380
[TBL] [Abstract][Full Text] [Related]
5. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis.
Peddie N; Agnew S; Crawford M; Dixon D; MacPherson I; Fleming L
Breast; 2021 Aug; 58():147-159. PubMed ID: 34049260
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction.
Billon R; Bosc R; Belkacemi Y; Assaf E; SidAhmed-Mezi M; Hersant B; Meningaud JP
J Plast Reconstr Aesthet Surg; 2017 Nov; 70(11):1495-1504. PubMed ID: 28676319
[TBL] [Abstract][Full Text] [Related]
7. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
9. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
10. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract][Full Text] [Related]
12. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
Gernier F; Grellard JM; Dupont C; Castel H; Fernette M; Lahaye F; Charles RM; Leroux T; Ory C; Faveyrial A; Morel A; Emile G; Levy C; Segura C; Allouache D; Johnson A; Geffrelot J; Gunzer K; Lelaidier A; Girault G; Dubot-Poitelon C; San C; Lequesne J; Clarisse B
BMC Cancer; 2023 Aug; 23(1):736. PubMed ID: 37559004
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Survivors' Lived Experience of Adjuvant Hormone Therapy: A Thematic Analysis of Medication Side Effects and Their Impact on Adherence.
Ibrar M; Peddie N; Agnew S; Diserholt A; Fleming L
Front Psychol; 2022; 13():861198. PubMed ID: 35602711
[TBL] [Abstract][Full Text] [Related]
14. Adherence and quality of life in women with breast cancer being treated with oral hormone therapy.
Stahlschmidt R; Ferracini AC; de Souza CM; de Medeiros LM; Juliato CRT; Mazzola PG
Support Care Cancer; 2019 Oct; 27(10):3799-3804. PubMed ID: 30729297
[TBL] [Abstract][Full Text] [Related]
15. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
17. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
